A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Terminated · Phase 1, Phase 2 · NCT04179864
Conditions: Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
At a glance
- Research payments reported, 2025
- $535,018
- U.S. investigators named
- 12
- Sites paid
- 13
- Planned or actual enrollment
- 102
About the trial
- Sponsor
- Epizyme, Inc.
- Tested
- Tazemetostat (drug), Abiraterone/prednisone (drug), Enzalutamide (drug)
- Dates
- Started 2019-11-18; completion 2024-11-04
- Results posted
- Yes
This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC. This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with eithe…
From ClinicalTrials.gov, last updated 2026-03-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $535,018 in research payments for this study in 2025 (53 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nicholas O. Iannotti, MD, FACP Hematology & Oncology · Port St Lucie, FL
- Bruce B. Bank, M.D. Hematology & Oncology · Elk Grove Village, IL
- Mary-ellen Taplin, MD Medical Oncology · Boston, MA
- Anna Ferrari, M.D. Hematology & Oncology · New Brunswick, NJ
- Holavanahall S. Keshava-prasad, MD Hematology & Oncology · Las Vegas, NV
- Wassim Abida, MD, PHD Hematology & Oncology · New York, NY
- Christopher M. Pieczonka, M.D. Urology · Syracuse, NY
- Leonard J. Appleman, MD Hematology & Oncology · Pittsburgh, PA
- Edward R. Arrowsmith, MD Hematology & Oncology · Chattanooga, TN
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- David S. Morris, MD Urology · Hendersonville, TN
- Daniel R. Saltzstein, MD Urology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UPMC Cancer Center $124,081
- Memorial Sloan Kettering Cancer Center $121,726
- Dana Farber Cancer Institute $98,884
- Sarah Cannon Cancer Institute at Hdh $66,554
- Urology San Antonio $48,167
- Biomedical Research Alliance of New York $29,423
- Hematology Oncology Associates of the Treasure Coast $14,633
- Associated Medical Professionals of Ny, PLLC $10,164
- Sarah Cannon Research Institute $9,747
- Urology Associates, PC $5,297
- Xcancer $5,124
- Comprehensive Cancer Centers of Nevada $869
- Dana-Farber Cancer Institute $350
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.